CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of CEL-SCI (NYSE:CVM) in a report issued on Thursday. The firm issued a sell rating on the stock.

CEL-SCI Trading Up 0.7 %

CVM opened at $0.30 on Thursday. The company’s 50 day moving average is $0.38 and its 200-day moving average is $0.68. CEL-SCI has a 1-year low of $0.29 and a 1-year high of $2.39. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. The company has a market cap of $23.47 million, a P/E ratio of -0.63 and a beta of 0.67.

Hedge Funds Weigh In On CEL-SCI

Several large investors have recently modified their holdings of CVM. Thoroughbred Financial Services LLC raised its stake in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after buying an additional 54,900 shares during the last quarter. Plotkin Financial Advisors LLC bought a new position in shares of CEL-SCI during the 3rd quarter worth about $98,000. Finally, Geode Capital Management LLC boosted its position in shares of CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after purchasing an additional 53,879 shares in the last quarter. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.